INDOBORAX · Indo Borax & Chemicals Ltd · Chemical Manufacturing
INDOBORAX · Indo Borax & Chemicals Ltd · Chemical Manufacturing
As of 05 Nov close
52-week range
19.7% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹70 Cr
Revenue YoY
PAT YoY
+59.3%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
3.8
P/S (TTM)
6.7
Sector P/E
20.6
Dividend yield
+2.1%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| INDOBORAX (this stock) | 20.2 | 3.8 | +24.3% | +14.6% | 0 | +2.1% |
| Solar Industries India | 99.6 | 26.6 | +17.6% | +31.4% | 13.68 | +0.1% |
| Asian Paints | 53 | 11.1 | +12.8% | +22.3% | 0.18 | +1.1% |
| Linde India | 114 | 12.2 | +20.6% | +12.8% | 0.02 | +0.1% |
Promoter
rising 1q
FII
falling 1q
MF
0.37%
stable
Insider trades
| Date | Insider | Type | Qty | Value |
|---|---|---|---|---|
| 30 Apr 2026 | Zenrock Chemicals Private Limited | BUY | 24,44,534 | ₹8 |
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| INDOBORAX | 2026-09-28 | 1773764 | 5 | WEAK | BULK |
| INDOBORAX | 2026-08-20 | 1064386 | 4 | MEDIUM | BULK |
| INDOBORAX | 2026-07-24 | 3208764 | 10 | WEAK | BULK |
| INDOBORAX | 2026-06-23 | 255632 | 1 | WEAK | BULK |
News timeline
- loweconomictimes.indiatimes.com· 23 Oct 2026, 06:00 amStocks in news: Swiggy, Infosys, HPCL, eMudhra, Adani Power, Shriram Finance, Tata Motors and NLC India
Concalls & investor presentations
AI-generatedKey takeaway: Indo Borax & Chemicals Limited reported a 31% increase in operating revenues and a 59% rise in net profits for Q1 FY27, with EBITDA and PAT margins at 28.1% and 22.3% respectively. The company highlighted its 50% market share in Boric Acid and recent acquisition of 64.26% of Kronox Lab Sciences, which is expected to expand its global presence and product portfolio. Management emphasized operational efficiencies, capacity optimization, and strategic acquisitions as key drivers of growth. The company also outlined plans for Capex of Rs. 50 crores over two to three years, focusing on Boron Oxide and Boric Acid expansions. The acquisition of Kronox includes a Rs. 110 crore Capex plan, funded through internal accruals and existing cash reserves. The company noted that while Q2 FY27 is expected to be weaker due to monsoon season, full-year revenue guidance remains at Rs. 250-260 crores with a 20% EBITDA margin. Strategic initiatives include cross-selling opportunities, expanding into higher-margin I.P. grade Boric Acid, and exploring import substitution under Atmanirbhar Bharat. The leadership team emphasized long-term value creation and integration of Kronox's global distribution network.
The document emphasizes strong financial performance, strategic acquisitions, and growth plans, with management highlighting confidence in future prospects and operational improvements.
Sourced from an exchange-filed transcript, dated 08 Sept 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings conference call for Indo Borax & Chemicals Limited, held on June 2, 2026, featured management discussing the company's performance for Q4 and FY2026. Managing Director Suresh Kalra highlighted a 23% growth in operating revenue and an 18% increase in net profit, attributing this success to new leadership, operational efficiencies, and improved product realizations. The company maintained a strong balance sheet with near-zero debt and announced a special dividend of Rs. 30 per equity share. The management emphasized plans for capacity expansion and diversification of product lines, particularly in Boron Oxide and Boric Acid I.P. grade. CFO Shashikant Bharuka provided detailed financial metrics, noting a 25.7% increase in Q4 operating revenue and a PAT margin improvement. The call concluded with management expressing commitment to sustainable growth and transparency with stakeholders.
Management emphasized strong financial performance and future growth opportunities.
Sourced from an exchange-filed transcript, dated 05 Jun 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Indo Borax & Chemicals Limited provided an investor presentation detailing its financial performance for FY26 and Q4 FY26. The company reported a consolidated revenue of Rs. 215.45 crore for FY26, marking a 22.9% year-over-year increase, with a net profit of Rs. 50.27 crore, up 18.3% from the previous year. For Q4 FY26, revenue reached Rs. 63.01 crore, a 25.7% increase year-over-year, while net profit rose by 41.9% to Rs. 14.53 crore. Management highlighted strong operational efficiencies and capacity utilization as key drivers of growth. The company declared a final dividend of Rs. 10 per share and a special dividend of Rs. 30 per share. Additionally, the presentation noted a significant ownership transition with a 50.80% stake sold to institutional investors in January 2026, indicating potential strategic changes. The company emphasized its leading position in the boric acid market and plans for future growth.
Management highlighted strong financial performance and strategic initiatives.
Sourced from an exchange-filed presentation, dated 28 May 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedIndo Borax & Chemicals Limited (INDOBORAX) reported financial results for FY2022-23, with no material audit issues or defaults noted. The company has a paid-up equity share capital of Rs. 320.90 lakhs as of March 31, 2023. A contingent liability arises from an Inter Corporate Deposit made to a party undergoing insolvency proceedings under the Insolvency and Bankruptcy Code, 2016. The company has filed a claim as a financial creditor and awaits the National Company Law Tribunal's decision. No interest has been provided on this loan due to uncertainty in realization. The company is expanding its production capacity with a new boric acid derivatives plant expected to commence operations by November 2023. The auditor's report did not contain any qualifications, reservations, or adverse remarks, except for the emphasis on the insolvency-related contingent liability. The company has not defaulted on loans or deposits and has maintained compliance with statutory requirements.
- Contingent liability of Rs. 8.667.59 lakhs from an Inter Corporate Deposit to a party in insolvency proceedings under IBC, with no interest provided due to uncertainty in realization.
- New boric acid derivatives plant installation expected to complete by September 2023, with production starting in November 2023.
- No defaults on loans or deposits, and no willful defaulter status as per banks or financial institutions.
- Auditor's report contains no qualifications, reservations, or adverse remarks except for the insolvency-related contingent liability.
- Company has not accepted public deposits, and no amounts on account of principal or interest on deposits from public were outstanding as of the balance sheet date.
Key takeaway: INDOBORAX faces a contingent liability from an Inter Corporate Deposit to a party in insolvency proceedings, but no defaults or audit issues were noted, with expansion plans underway.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Auditor Qualification (1 item); Regulatory Action (1 item); Default / Covenant Breach (2 items)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Auditor Qualification
1 occurrenceEarlier (1-3 years ago)
The auditor's report includes an emphasis of matter regarding a party in insolvency proceedings, with the company having filed a claim as a financial creditor and awaiting the National Company Law Tribunal's outcome.
Regulatory Action
1 occurrenceEarlier (1-3 years ago)
The company was fined Rs. 6.65 Lakhs plus GST by the exchange for not complying with regulation 17(1) regarding board composition, despite having appointed directors within the stipulated 90 days.
Default / Covenant Breach
2 occurrencesEarlier (1-3 years ago)
The company has a net default in the repayment of loans or other borrowings or in the payment of interest thereon to any lender.
The company has a loan to a party undergoing insolvency resolution, with the outcome pending at NCLT. The company is not providing interest on the loan for the financial year ended 31 March 2024 due to uncertainty in debt realization.
Routine disclosures
Internal Control Weakness
2 occurrencesEarlier (1-3 years ago)
The auditors have issued an adverse audit opinion on the Company's internal financial controls system over financial reporting.
The auditor issued an adverse audit opinion on the Company's internal financial controls system over financial reporting.
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
The company has a related-party transaction with Kadi us Estate Projects Private Limited, which is undergoing corporate insolvency. The company has filed a claim for Rs. 509.04 Lakhs as a financial creditor and is awaiting the outcome from the National Company Law Tribunal.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
40.57% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).